Force Degradation Study as per ICH Guidelines

When a drug material or drug product is exposed to various stress conditions—more severe than accelerated conditions—forced degradation occurs, producing pertinent degradation products. Drug stability can be predicted with the use of purposefully applied forced deterioration. Drug stability is an important factor that affects the product's safety, potency, and purity. For example, alterations in drug stability may lead to hazardous breakdown products or reduced dosages. Thus, understanding a drug's behavior and purity profile under different circumstances is essential ^[1].

Stress testing, stress studies, stress decomposition studies, forced decomposition studies, etc. are other names for forced degradation research. Forced degradation is a procedure that produces degradation products that may be examined to ascertain the stability of the molecule by subjecting drug ingredients and products to conditions more severe than accelerated conditions ^[2].

To accelerate the chemical, physical, or instability of a molecule, forced degradation investigations employ a variety of stressing stimuli, including pH, temperature, light, chemical agents (such as oxidizing and deamidating agents), and mechanical stress. In order to determine the degree and rate of deterioration that is anticipated to occur during storage and/or following administration to the body, forced degradation experiments involve exposing the pharmacological ingredient to a variety of stress conditions ^[3].

Relevant stress variables in a typical study include light, heat, humidity, oxidation, hydrolysis (acid/base effect), and even a combination of these parameters. Forced degradation studies are required by regulatory bodies to show that analytical techniques employed in pharmaceutical analysis are specific. The ability of analytical techniques to distinguish active pharmaceutical compounds from degradation products, contaminants, and excipients is confirmed through stress testing^[4]. Pharmaceutical companies conduct these stress tests (also known as forced degradation studies) during preformulation in order to choose suitable parameters, such as sample production for creating stability-indicating analytical methods, compounds and excipients for additional development, and formulation optimization. Preformulation studies are involved, but stress testing can be repeated during product composition, manufacturing processes, and analytical procedures ^[5].

According to FDA and ICH guidelines, the quality of a drug substance and drug product varies over time due to a variety of environmental conditions. Forced decomposition studies are used to investigate the stability of the molecule, various degradative pathways, and validation of the devised stability protocols in accordance with the guidelines of the International Committee for Harmonization (ICH). The Food and Drug Administration (FDA) and ICH guidelines provide a clear explanation of the specifics of drug molecules that decompose and the various products that are created in relation to time changes under the influence of various environmental parameters and comprehension of stability data ^[6].

According to the ICH recommendation, stress testing is meant to validate the stability-indicating techniques employed and to identify the expected degradation products, which further aids in determining the intrinsic stability of the molecule and defining degradation pathways ^[7].

Need of Force Degradation 1. To create techniques for assessing stability. 2. To identify the paths of deterioration. 3. To ascertain the drug's intrinsic stability in dose formulations. 4. To research molecules' chemical characteristics. 5. To create formulas that are stable. 6. To ascertain the breakdown products' structure. 7. To produce a deterioration profile under ICH circumstances. 8. Knowing how degradation occurs. 9. Encouraging validation of analytical methods 10. To find contaminants associated with medication ingredients or excipients 11. To comprehend the chemistry of medication molecules. 12. To produce formulations that are more stable. 13. To address stability-related issues ^[8].

Source of Degradation Product

Degradation is the primary cause of contaminants appearing in pharmacological substances or products. The primary source of the drug's deterioration is its chemical instability under the heat, humidity, solvent, pH, and light conditions encountered during production, isolation, purification, drying, storage, transportation, and/or formulation. It is controlled by the drug's intrinsic chemical stability. Any drug compound can degrade primarily by hydrolysis, oxidation, heat, and photolysis. Stress testing facilitates the creation of all potential degradation products that could arise under various circumstances ^[9].

Degradation limits

In order to understand the degradation chemistry of drug ingredients and drug products, forced degradation is a crucial step in the drug development process. Developing stability-indicating analytical techniques is the main use of this information, but it can also be applied to formulation, packaging, and official stability study design. It is advised to employ proper degradation since there is no official regulatory guideline for forced deterioration. Requirements to reach 5–20% ^[10].

Drug concentration selection

Regulatory guidelines do not specify how much medication concentration should be utilized for degradation studies. The concentration of 1 mg/ml should be used for the stress state. Drug degradation should occur even at low concentrations. It is recommended that the concentration at which the drug is anticipated to be present in the final formulations be used for the degradation research ^[11].

Analytical methods for characterizing forced deterioration studies

Studies on forced degradation can be created utilizing a variety of methods. High performance liquid chromatography, or HPLC, is the most practical approach. The main reasons RP-HPLC is selected are its high sensitivity, high precision, high accuracy, and compatibility with a wide range of organic and aqueous solutions, as well as its capacity to extract or identify polar molecules. A suitable column type, column temperature, pressure, and mobile phase pH are all chosen throughout the degradation study's development stage ^[12].

2) Experimental approach

The ideal outcome of the experimental protocol for degradation studies of novel drug substances and drug products is samples that have either undergone approximately 10% degradation or have been exposed to a quantity of energy that marginally surpasses that provided under accelerated storage conditions (e.g., 40°C for six months). Anytime a stability-indicating approach is needed, forced degradation tests should be carried out. When techniques, procedures, or formulations change, studies may need to be repeated. Alternatively, if available, a combination of the known degradation products can be used to develop methods. Before starting formal stability studies, each unique formulation should undergo forced degradation studies ^[13].

Timing of stress testing studies: The majority of companies perform studies on the drug substance and the drug product in the preclinical stage. The practice of repeating stress testing studies varies by stage of development. Studies are repeated on the drug substance between the preclinical and registration stages, and studies are repeated on the drug product between Phase I and registration as the final commercial formulation is developed ^[14].

Table 1: Overview of Force Degradation

1.Hydrolytic Degradation

A chemical process called hydrolysis involves breaking down a chemical molecule by an interaction with water. Hydrolytic research involves the catalysis of the molecule's ionisable functional groups under both basic and acidic environments. When a pharmacological material is subjected to acidic or basic conditions, it is driven to degrade and produce primary degradants in a desired range. This process is known as acid or base stress testing. The choice of acid or base type and concentration depends on the pharmacological substance's stability ^[15].

Mechanism

Water divides the molecule during hydrolysis by acting as a reactant. This typically happens when: a. Acid (acidic hydrolysis)

b. Base (hydrolysis of alkaline)

c. Neutral Hydrolysis (lower rate)

The overall response can be expressed as follows:

Drug + H ₂ O = Degraded Products

a. Acid Hydrolysis Degradation

The stability of medicinal compounds in acidic environments is assessed using acid hydrolytic stress testing. The medication is usually subjected to acids at room temperature or at higher temperatures, such as sulfuric acid (H2SO4) or hydrochloric acid (HCl), in concentrations between 0.1 M and 1 M.

One popular method is to expose the drug solution to an acidic pH (around pH 2) for up to two weeks, or until 10–15% degradation is attained. The medication may be refluxed in 0.1 N HCl for eight hours in order to perform a first screening. Stronger conditions, like 1 N HCl for 12 hours and then 2 N HCl for 24 hours, may be used if degradation is not sufficient.

Harsher conditions, like 5 N HCl reflux for 24 hours, can be utilized if the medication still exhibits stability. In acidic environments, a medication that exhibits no degradation under such harsh circumstances can be regarded as practically stable.

On the other hand, the study should be repeated with a lower acid content (0.01 N HCl), a lower temperature (such as 40°C or 25°C), and a shorter duration if severe degradation happens under mild conditions.

b. Base Hydrolysis Degradation

Base hydrolysis assesses a drug's vulnerability to alkaline breakdown. Potassium hydroxide (KOH) or sodium hydroxide (NaOH) in concentrations ranging from 0.1 M to 1 M are typical reagents. The investigation is often carried out at ambient or high temperatures with an alkaline pH (10–12). For the first test, the medication may be refluxed in 0.1 N NaOH for eight hours. The strength can be gradually increased to 1 N, 2 N, and up to 5 N NaOH with longer reflux durations if deterioration is not seen.

To prevent total destruction, milder conditions (such as 0.01 N NaOH) should be applied to medications that are known to include ester or amide functional groups, which are extremely vulnerable to alkaline hydrolysis.

The medicine is deemed extremely labile in alkaline settings if total breakdown happens even in mild conditions. Testing should be carried out in controlled, less hostile environments (lower temperature and shorter duration).

Figure 1: Pathway of Acid and Base Degradation Study for Drug Substance and Drug Product

c. Neutral Hydrolysis Degradation

To evaluate medication stability in aqueous (water) conditions without the addition of acid or base, neutral hydrolysis experiments are conducted. The medication is routinely refluxed in water for 12 hours as an initial condition. If no degradation is seen, the time may be raised progressively to 24 hours, 48 hours, and up to 5 days.

If the medicine stays stable even after lengthy exposure, it can be called stable under neutral hydrolytic circumstances. On the other hand, if significant deterioration occurs under initial conditions, the exposure should be lowered to 8 hours at 40°C or further to 2 hours at 25°C to find gentler degradation behavior.

In order to increase the experiment duration without having to redo the study, it is advised to utilize an adequate beginning volume of solution ^[16].

Figure 2: Pathway of Hydrolysis in Neutral Condition for Drug Substance and Drug Product

2.Oxidation Degradation

It is discovered that the majority of pharmacological compounds are auto-oxidizers. For the oxidation process, they need free radical initiators. Free radicals are initiated by metal ions, hydrogen peroxide, and traces of contaminants. Electrons are transferred during this kind of deterioration. A typical initiator for oxidation driven degradation research is 0.1–3% hydrogen peroxide. These investigations ought to be carried out for one to seven days at 40°C. It should be regarded as abnormal if more than 20% degradants are generated ^[17].

Degradation by oxidation can be complicated. Other oxidizing agents including metal ions, oxygen, and radical initiators (e.g., azobisisobutyronitrile, AIBN) can also be employed, even though hydrogen peroxide is primarily utilized to simulate the potential existence of peroxides in excipients. The drug ingredient determines which oxidizing agent to use, how much of it to use, and under what circumstances. Oxidative degradation can occur in drug substance solutions and solid/liquid drug preparations.

Procedure for Oxidation Degradation

Relevant degradation products may be produced by exposing the solutions to 0.1%–3% hydrogen peroxide at neutral pH and room temperature for seven days or up to a maximum of 20% degradation. To ascertain the appropriate degree of degradation, samples can be examined at various periods.

Testing can begin by immersing the medicine in 3% H2O2 for six hours at room temperature in order to ascertain the drug's susceptibility to oxidative breakdown. If there is insufficient degradation, the reaction time should be extended to 24 hours. The reaction should be carried out in 10% H2O2 for 24 hours if nothing changes. More severe conditions of 30% H2O2 for 24 hours may be tested for a medication that does not oxidize even in these circumstances. If no products are generated when the medicine is subjected to this situation, it may be deemed "practically stable."

The intensity of H2O2 should be reduced from 3% to 1% in the case that the entire drug decomposes under the initial conditions. The reaction can then be observed for a long enough time to produce the required percentage of decomposition. Drugs that completely degrade even in these circumstances are extremely vulnerable and should be examined in very diluted oxidizing agents with brief exposure times.

Figure 3: Pathway of Oxidation Degradation Study for Drug Substance and Drug Product

3.Thermal Degradation

It has been shown that a number of medications are thermolabile. Degradation products are produced when the temperature rises since the rate of reaction likewise tends to rise. The ideal temperature range for these investigations is between 40 and 80°C. Thermal stress experiments are often carried out at 70°C and high humidity for one to two months. Liquids are exposed to dry heat for a shorter period of time than solid drug molecules, which are exposed to both dry and wet heat conditions. The drug molecule degrades as a result of the high temperature, as indicated by the Arrhenius equation:

k = Ae-Ea/RT

where k: Specific reaction rate, A: Frequency factor, Ea: Energy of activation, R: Gas constant (1.987 cal/deg/mole), and T: Absolute temperature in Kelvin.

• Procedure for conducting thermal degradation

Conduct the following forced degradation studies to obtain degraded samples wherever degradation possible from about 1% to 30%. Preferably, the following stress conditions are recommended for specificity study, however stress condition can be decided based on experimental data, or physical properties of the analyte based on literature. If melting point of API is less than 150°C, stress at 105°C or 40°C less than melting point whichever is higher. If melting point of API is more than 150°C stress at the nearest melting point and at 105°C ^[18].

5.Humidity Degradation

One useful tool for identifying possible degradants in the final product and active medicinal ingredient is humidity. For the development of forced deterioration samples, 90% humidity for a week is typically advised ^[19].

5.Photolytic Degradation

In photolytic degradation studies, the drug substances are exposed to UV or fluorescent conditions. In this study, the drug substances or drug products (solid/liquid) are exposed to the light source according to the ICH Q1B protocols. The commonly used radiation range for degradation studies is about 300–800 nm. In photolytic condition, the degradation occurs due to oxidation through free radical mechanism or non-oxidation process. Non-oxidative degradation process involves with isomerization, dimerization, etc., among others. On the other hand, oxidative photolytic reaction involves mechanism involving singlet/triplet oxygen states. Singlet oxygen reacts with unsaturated compounds to produce photooxidative decomposition products, while triplet oxygen follows free radical mechanism, to produce a peroxide. Notably, it is shown that light also catalyzes oxidation reactions.

• Procedure for conducting photolytic degradation

Wherever possible, collect deteriorated samples from 1% to 30% by doing the following forced degradation investigations. Expose the tablet powder contents of the capsule to ultraviolet light up to a minimum of 200 watts hour/m2 and a minimum of 1.2 million lux hours for the photo stability chamber and visible light. If a photo stability chamber isn't available, expose the tablet powder or capsule contents to intense UV light for at least seven days in a UV cabinet, both at longer and shorter wavelengths.

Figure 4: Pathway of Photo Degradation Condition for Drug Substance and Drug Product

Figure 5: Flow Path for Structural Elucidation of Degradation Product

Table 2: Frequently Used Conditions for Force Degradation Studies

3) ICH regulatory guidelines for forced degradation

1. ICH Q1A (R2) – Stability Testing of New Drug Substances and Products

General Principle

Stability testing is conducted to evaluate how the quality of a drug substance or product changes over time under environmental factors such as temperature, humidity, and light. The data obtained are used to determine the re-test period, shelf life, and recommended storage conditions.

The testing conditions specified in ICH guidelines are based on climatic data from major regions- Europe, Japan, and the United States. Using mean kinetic temperature, the world is divided into four climatic zones (I–IV), although the guideline mainly focuses on Zones I and II.

A key principle of ICH is the mutual acceptance of stability data among these regions, provided the studies follow the guideline and comply with regional labeling requirements. This harmonized approach helps ensure consistent quality evaluation and avoids duplication of studies globally.

Further chemical degradation reactions, such as oxidation, reduction, hydrolysis, and racemization, impart a crucial role in a pharmaceutical product’s stability. The conditions such as reactant concentration, pH, radiation, catalysts, raw materials, and the duration between manufacture and usage of the product also affect the stability of the drug product. The physical changes, such as vibration, and temperature variations, like freezing, shearing, and thawing, may impact, on the product stability, which may result in loss of potency of the active pharmaceutical ingredient ^[20].

Recommended conditions for performing forced degradation studies on drug substances and drug products. The recommendations are to inspect the results of temperature (above that for accelerated testing, i.e., >50 C), humidity (75% relative humidity), oxidation and photolysis. Wide pH range should be considered in the testing of solution or suspension. Ultimately the stability-indicating method developed by these samples ^[21].

Scope of Guideline

• The guideline applies to new molecular entities (NMEs) and their associated drug products submitted for registration.
• It provides requirements for stability data in full (new) drug applications.
• It does not cover: Abbreviated or generic applications, Variations or post-approval changes, Clinical trial applications
• Detailed procedures for sampling and testing of specific dosage forms in their container-closure systems are not included.
• Additional guidance for special categories is provided separately:
• ICH Q1C → for new dosage forms
• ICH Q5C → for biotechnological/biological products ^[22].

Stages of stability studies

Stability studies are conducted at every stages of the drug life cycle from 1st stages of product development to late stage follow up studies. There are 6 different stages:

Stage 1: Early stage i.e., stress and accelerated testing with drug substances.

Stage 2: Stability on pre-formulation lots/batches.

Stage 3: Stress test done on scale up batches.

Stage 4: Accelerated and long-term testing for registration purposes.

Stage 5: Enduring stability testing.

Stage 6: Follow up studies ^[23].

2. ICH Q1B – Photostability testing of new drug substances and products

The ICH Harmonized Tripartite Guideline (Q1A) states that light exposure testing is an essential part of stress testing. Photostability testing ensures evaluation of the effect of light on drug substances and products. This document (ICH Q1B) acts as an annex to the parent guideline (Q1A). It provides specific recommendations and procedures for conducting photostability studies.

The aim is to determine whether light exposure leads to degradation and to establish appropriate protective measures (e.g., packaging, labeling). The intrinsic photostability of drug substances and products must be evaluated to ensure that light exposure does not cause unacceptable degradation. Photostability testing is usually performed on a single batch selected according to ICH Q1A guidelines.

• Repeat studies may be required if there are changes such as: Formulation and Packaging.
• The need for repetition depends on Initial photostability results and Nature of the changes made
• The guideline focuses on generating photostability data for registration applications of new drug substances and Drug products
• It does not cover: Photostability after drug administration (in-use conditions), Applications outside the scope of the parent guideline
• Alternative approaches can be applied if they are: Scientifically justified and Properly documented ^[24].

3. ICH Q2 (R1) – Validation of Analytical Procedures

• This document discusses key characteristics for validating analytical procedures used in registration applications in Europe (EC), Japan and United States.
• It is mainly intended for harmonization among these regions and may not fully apply to other parts of the world. The guideline provides a collection of standard terms and definitions related to validation. It is not a detailed procedural guide, meaning it does not explain how to perform validation step-by-step. The definitions help to reduce differences between pharmacopeias and regulatory authorities.
• The main objective of validation is to demonstrate that an analytical method is suitable for its intended purpose. It includes a tabular summary of validation parameters for: Identification tests , Impurity testing and Assay methods

Types of Analytical Procedures to be Validated

The discussion of the validation of analytical procedures is directed to the four most common types of analytical procedures: -

• Identification tests
• Quantitative tests for impurities' content
• Limit tests for the control of impurities
• Quantitative tests of the active moiety in samples of drug substance or drug product or other selected component (s) in the drug product.

METHODOLOGY:

• This document is supplementary to the parent guideline (ICH Q2) on analytical method validation.
• It provides guidance and recommendations on how to evaluate different validation characteristics for analytical procedures.
• Emphasizes that multiple analytical methods may be used together to ensure overall quality of the Drug substance and drug product
• In certain cases (e.g., specificity), combined analytical approaches may be required to demonstrate reliability.
• It also outlines the type of validation data that should be included in Registration applications ^[25].

4. ICH M4Q (R1) –The common technical document for the registration of pharmaceuticals for human use: Module 3: Quality

The guideline provides a standardized format for preparing registration applications for drug substances and drug products, particularly those covered under ICH Q6A (for new chemical entities) and ICH Q6B (for biotech products). It may also be applicable to other product categories, depending on consultation with regulatory authorities.

The document mainly serves as a structural guide, explaining how information should be organized rather than specifying exact data requirements. The content under each section is illustrative, and applicants are expected to include relevant details based on existing ICH guidelines and regional regulatory expectations.

Importance

The guideline identifies where information should be placed in the application (Body of Data), but it does not define the exact type or amount of data required, as this may vary by region.

Additionally, Part 3.2.R (Regional Information) includes sections that differ across regions, meaning applicants must follow specific regional regulatory requirements for those parts ^[26].

5. ICH Q3A (R2) - Impurities in new drug substances

ICH Q3A guidelines provide information about the determination of contaminants present in new drug molecules. This section provides insights about different aspects such as the identification, types and specification of impurities, analytical protocols, and generation of reports. More importantly, if the impurities are either completely absent or present in trace amounts in batch of a new drug molecule is considered helpful to ensure safety toward clinical studies.

Classification of impurities

i. Organic impurities (process- and drug-related)

ii. Inorganic impurities

iii. Residual solvents

• Organic impurities can arise during the manufacturing process and/or storage of the new drug substance. They can be identified or unidentified, volatile or non-volatile, and include: Starting materials, By-products, Intermediates, Degradation products, Reagents, ligands and catalysts.
• Inorganic impurities can result from the manufacturing process. They are normally known and identified and include: Reagents, ligands and catalysts, Heavy metals or other residual metals, Inorganic salts, Other materials (e.g., filter aids, charcoal)
• Solvents are inorganic or organic liquids used as vehicles for the preparation of solutions or suspensions in the synthesis of a new drug substance ^[27].

6. ICH Q3B -Impurities in new products

ICH Q3B provides information about analytical procedures. It is important for an analytical procedure to validate the specific or non-specific degradation products under various stress conditions.

7. FDA Guidance- Analytical procedures and method validation for drugs and Biologics

This guidance provides recommendations for submitting analytical procedures and validation data for DS/DP covered under NDA, ANDA and BLA. It encompasses information on analytical method development, validation and life cycle management of analytical procedures. It also discusses the content of analytical procedures, reference standard and materials. In sec 4, analytical method validation, reference is made to the samples undergoing exposure to stress conditions to demonstrate specificity. If an analytical method is transferred to another lab, it is stability indicating method. It is recommended that stressed samples be analysed at both sites.

FDA Guidance: Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products

In this guidance, the FDA recommends that the applicant follow ICH stability guidance Q1 A, Q1 B, Q1 C, Q1 D and Q1 E for submission batches. Thus, the stress studies must be performed as mentioned in Q1A and Q1B. If the applicant follows an alternate approach, they must justify it to the FDA ^[28].

4) Application of Force degradation in Analytical Chemistry

1. Development of Stability-Indicating Methods

• Post-degradation studies are widely used to develop stability-indicating analytical methods (e.g., HPLC, LC-MS).
• They help ensure that the method can separate the drug from its degradation products.
• This is essential for accurate quantification of the active pharmaceutical ingredient (API) in the presence of impurities.

2. Identification of Degradation Products

• Helps in identifying and characterizing degradation products using techniques like LC-MS, GC-MS, NMR.
• Provides insight into chemical structure changes after degradation.
• Supports impurity profiling required by regulatory guidelines ^[29].

3. Elucidation of Degradation Pathways

• Determines how a drug degrades under different stress conditions.
• Helps establish degradation mechanisms (e.g., hydrolysis, oxidation).
• Useful in predicting long-term stability behavior.

4. Validation of Analytical Methods

Post-degradation samples are used during method validation to demonstrate:

• Specificity (ability to distinguish analyte from degradation products)
• Accuracy and precision in degraded conditions
• Compliance with regulatory requirements ^[30].

5. Stability Studies and Shelf-Life Determination

• Supports real-time and accelerated stability studies.
• Helps in estimating shelf life and storage conditions.
• Identifies conditions that may lead to rapid degradation ^[31].

6. Formulation Development

• Assists in selecting suitable excipients and formulations.
• Helps avoid interactions that may cause degradation.
• Improves overall product stability.

7. Regulatory Compliance and quality control

Post-degradation studies are required by guidelines such as:

• International Council for Harmonisation (ICH Q1A, Q1B, Q2, Q3B)
• For drug approval
• To ensure product quality and safety
• Ensures compliance with global regulatory standards for drug approval ^[32].

8. Quality Control and Quality Assurance

• Used in routine QC testing to ensure product consistency.
• Helps detect impurities and degradation products during manufacturing and storage.

9. Packaging and Storage Optimization

• Helps determine the effect of environmental factors like light, oxygen, and moisture.
• Assists in selecting appropriate packaging materials (e.g., amber bottles, blister packs).

10. Comparative Stability Studies

• Used to compare stability of different formulations or batches.
• Important in generic drug development to ensure equivalence with innovator products.

11. Toxicological Evaluation

• Identifies potentially toxic degradation products.
• Ensures safety of the drug product throughout its shelf life.

12. Process Development and Optimization

• Helps understand degradation during manufacturing processes.
• Assists in optimizing conditions to minimize degradation.

13. Application of Chemometrics and Advanced Data Analysis

Modern analytical chemistry integrates:

• Multivariate analysis
• Chemometric tools for degradation data interpretation
• Chemometrics enhances interpretation and optimization of degradation studies ^[33].

5) Overall benefits of forced degradation studies in assessing drug/product stability

Several official documents highlight the following advantages of stress testing during stability testing: i.An assessment of the drug's or product's overall sensitivity to several elements and their combinations, including heat, humidity, pH, oxygen, light, and catalysts. ii.Clarification of the active ingredient's intrinsic stability properties. iii. The creation of samples needed to outline degradation and identify the degradation products produced under various stress situations ^[34].

6) Factors Affecting FDS Use- All businesses conduct forced deterioration studies to support comparability, according to respondents to the Bio-forum poll. However, not all comparison studies require or require a forced deterioration study. Numerous factors influence the scope and design of FDS.

The extent of changes in the manufacturing processes is a key driver in deciding whether to implement FDS as part of the comparability assessment. A common approach among all responding companies is to use ^[35].

7) Factors affecting stress degradation

The following are the many factors that induce drug substance degradation. They are as follows:

i. Temperature: Variations in temperature may have an adverse effect on the stability of the medication. As the temperature rises, the rate of medication hydrolysis increases dramatically. ii. pH: pH has a major impact on the pace of medication hydrolysis degradation. Pharmaceutical formulations use pH-stable buffer solutions to get around this. iii. Light: A number of medications are photolabile, meaning they break down in the presence of light. By contrasting the stability of the material in the presence of light with the stability of the material when stored in the dark, one can ascertain the sensitivity to photolytic deterioration.

iv. Moisture: When moisture is present, water-soluble substances may be absorbed. Consequently, the molecule experiences both chemical and physical changes. v. Oxygen: The presence of oxygen increases the oxidation of some medications. Drugs that break down more quickly in the presence of oxygen are stabilized by the purifying nitrogen or carbon dioxide from the storage container ^[36].

vi. Excipient: It was noted that certain excipients can have a high water content. This moisture may cause the formulation's water content to rise, which would subsequently impact the drug's stability. Chemical photolytic breakdown can sometimes be evaluated by contrasting its stability in the presence of light with stability in the absence of light. Photo-labile compounds should be kept in dark, amber glass containers. Decreased stability is frequently the outcome of interactions between the medication substance and the excipient ^[37].

vii. Nature of Drug Substance: The drug's chemical structure is crucial to its breakdown; for example, functional groups like phenols, amides, lactams, and esters are very prone to breakdown. The sensitivity to oxidation is increased when double bonds are present. Stability is also impacted by chemical complexity and stereochemistry.

8) Techniques used in analysis of stability samples

i.Titrimetric and spectrophotometric- This method analyzes only the drug of interest in the presence of excipients, additives, contaminants, degradation products, etc., as well as other drug components in the case of combination products. The primary benefits are simplicity and affordability, but occasionally they are shown to be less sensitive. Due to their lack of specificity, there are very few reports on their utilization these days ^[38]. ii.Chromatographic : Among its benefits are increased sensitivity, accuracy, and multicomponent separation. Gas chromatography (GC), capillary electrophoresis (CE), thin-layer chromatography (TLC), high-performance thin-layer chromatography (HPTLC), and HPLC are some of the chromatographic techniques that have been employed.

iii. Miscellaneous: While CE is currently one of the newest methods for the development of SIAMs, proton nuclear magnetic resonance (H-NMR) spectroscopy has been used for the establishment of SIAMs in previous reports. It has the advantage of high resolution, sensitivity, and high efficiencies with minimal peak dispersion. The different hyphenated methods, such as GC-MS, LC-MS, LCMS-MS, LC-NMR, and CE-MS, for the selective determination and identification confirmation of known and unknown degradation products ^[39].

9) Impurity Profiling of Force Degradation

The term "impurity profiling" describes a collection of analytical techniques used to identify, quantify, and clarify the presence of both organic and inorganic contaminants, such as residual solvent in pharmaceutical and bulk dosage forms ^[40]. An impurity profile for the active pharmaceutical ingredient is an essential quality control metric that is used throughout the whole process of developing, manufacturing, and testing pharmaceutical formulations for stability ^[41], with equal weight given to the quantity and quality of impurity details ^[42].

Reversed phase HPLC is a universal analytical tool for characterizing forced degradations and then identifying and measuring the impurities or degradants. As a result, forced degradation research became a crucial component of HPLC. Knowing the likely types of molecular attachments both before and after degradation is made easier with the use of infrared spectroscopy^[43]. It comprises the type of each identified impurity, its range, and its identification or some qualitative analytical classification. The maximum number of impurity types that can be found in a substance under investigation is indicated by its impurity profile. The procedure or source of the API typically affects the impurity profile.

Degradation product: Degradation products are only impurities. "A molecule resulting from a change in the drug substance brought about over time" is the definition of degradation products.

Unspecified impurities and unspecified Degradation products: Impurities or degradation products that are limited by general acceptance criteria but not individually listed with their specific acceptance criteria in individual monographs.

Specified impurity: A specified impurity is one that is included separately in the new drug substance specification and is restricted by a particular acceptance criterion. It is possible to identify or not identify a certain impurity.

Process Contaminant: Reagents, catalysts, and other inorganic impurities are examples of known or unknown process pollutant. Foreign chemical may also be included.

Unidentified Impurities and Unidentified Degradation Products: These are impurities or degradation products that are only identified by qualitative analysis properties and for which structural characterization has not been accomplished.

Foreign substances (Extraneous contaminants): An impurity that arises from any sources extraneous to the manufacturing process and that is introduced by contamination or adulteration

Stereometric Impurity: A compound with the same 2-dimensional chemical structure as the drug substance but differs in the 3-D orientation of substituents at chiral centres within that structure.

Toxic Impurities: Toxic impurities have significant undesirable biological activity, even as minor components, and require individual identification and quantification by specific tests ^[44].

Analytical techniques used in impurity profiling and force degradation study

Impurities can be monitored using a variety of approaches. These approaches are illustrated in the below-mentioned techniques ^[45].

Figure 6: Schematic Representation of Scheme for Impurity Profiling of Drugs

10) Future Perspectives of Forced Degradation Studies (as per ICH Guidelines)

According to ICH guidelines like Q1A (R2), Q1B, and Q2 (R1), forced degradation studies are crucial for comprehending drug stability and creating stability-indicating techniques. However, several gaps and evolving trends indicate significant future advancements in this field.

1. Need for More Specific Regulatory Guidance

• Current ICH guidelines provide general recommendations but lack detailed protocols for stress conditions and endpoints.

• Future Perspectives:

• Standardized stress conditions (temperature, pH, oxidants)
• Defined degradation limits (e.g., % degradation targets)
• Harmonized global regulatory expectations
• This will reduce variability and improve reproducibility across pharmaceutical industries.

2. Science-Based Endpoint Determination

• One major limitation is the absence of clear endpoints for “sufficient degradation.”

• Future Perspectives:

• Data-driven endpoints (5–20% degradation or stress-based endpoints)
• Avoidance of over-stressing (non-relevant degradation products)
• Drug-specific degradation criteria
• This will ensure realistic and meaningful degradation pathways.

3. Integration with Quality by Design (QbD)

• Forced degradation is increasingly being linked with Quality by Design (QbD) concepts.

• Future Perspectives:

• Identification of Critical Quality Attributes (CQAs)
• Risk-based selection of stress conditions and Better control of formulation and manufacturing processes

4. Advanced Analytical Techniques

• Future FD studies will rely heavily on:
• LC-MS/MS, HRMS, UPLC and NMR spectroscopy
• Hyphenated techniques (LC-MS, GC-MS)
• These techniques allow:
• Accurate identification of degradation products
• Structural elucidation at trace levels
• Improved sensitivity and selectivity ^[46].

5. Application of Chemometrics and AI

• Emerging trends include chemometrics and artificial intelligence for data interpretation.

• Future Perspectives:

• Predictive modelling of degradation pathways and AI-based stability prediction
• Multivariate analysis for stress condition optimization
• This will reduce experimental workload and improve efficiency.

6. Expansion to Biopharmaceuticals

• Traditional FD studies were mainly for small molecules, but now expanding to: Proteins, monoclonal antibodies, Vaccines.

• Future Perspectives:

• Understanding complex degradation mechanisms (aggregation, deamidation, oxidation)
• Comparability studies as per ICH Q5E

7. Lifecycle-Based Approach

• FD studies are no longer a one-time activity but are evolving throughout: Preclinical stage, Clinical development ,Post-approval changes

• Future Perspectives:

• Continuous updating of degradation knowledge throughout product lifecycle ^[47].

CONCLUSION

Designing a forced degradation study to meet the expectations of ICH Q1A (R2) and Q2 (R2) involves multiple stages, from defining objectives to analyzing results. By adhering to regulatory guidelines and applying structured methodologies, pharmaceutical professionals can create robust stability-indicating methods that confirm the quality and reliability of their products. Continuous monitoring of forced degradation studies assists in understanding degradation pathways, allowing companies to remain proactive in their development processes and ensuring that safety and quality standards are consistently met. Forced degradation studies, as per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, are essential to understand the stability and degradation behaviour of drug substances. These studies help in developing stability-indicating methods, identifying degradation pathways, and ensuring drug safety, quality, and efficacy. Overall, they play a key role in pharmaceutical development and regulatory approval.

REFERENCES

1. Von V, Helene J, Aus S. Forced degradation studies – comparison between ICH, EMA, FDA and WHO guidelines and ANVISA’s resolution RDC 53/2015. 2015.
2. Rawat T, Pandey IP. Forced degradation studies for drug substances and drug products: scientific and regulatory considerations. J Pharm Sci Res. 2015;7:238-41.
3. Schmidt AS. Forced degradation studies for biopharmaceuticals. Pharm Technol. 2016;40:54-7.
4. Brummer H. How to approach a forced degradation study. Life Sci Tech Bull. 2011;31.
5. MET's Institute of Pharmacy, Nashik. A review on forced degradation studies, stability indicating methods of antiviral drugs. J Pharm Neg Results. 2022;13 (Special Issue 1).
6. Charde MS, Kumar J, Velankiwar AS, Chakole RD. Development of forced degradation studies of drugs: a review. Int J Adv Pharm. 2013;2:34-9.
7. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs: a review. J Pharm Anal. 2014;4 (3):159-65. doi:10.1016/j.jpha.2013.09.003.
8. Shanmuga Kumar D. Forced degradation: a review. Biomed J Sci Tech Res. 2022;47 (3).
9. Charde MS, Kumar J, Welankiwar AS, Chakole RD. Forced degradation studies in pharmaceutical development: a review. Int J Adv Pharm. 2013;2 (3):34-39.
10. Singh A, Singh P, Shukla D. Technical considerations of forced degradation studies of new drug substances and product: regulatory perspectives. J Drug Deliv Ther. 2018;8 (2):163-8. doi:10.22270/jddt.v8i2.1681.
11. Thakor KA, Bhavsar DD, Thakor JR. Development of forced degradation and stability indicating studies for drug substance and drug product: a review. Int J Res Pharm Sci. 2017;8 (3):XXX-XXX.
12. Durgule SM, Patil PM, Kore AP, Singh MT, Kadam SD. An introduction to forced degradation studies for drug substance and drug products. J Emerg Technol Innov Res. 2021;8 (9):c260-c265.
13. Reynolds DW, Fachine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. Available guidance and best practices for conducting forced degradation studies. Pharm Technol. 2002;26:48-56.
14. Alsante KM, Martin L, Baertschi SW. A stress testing benchmarking study. Pharm Technol. 2003;27:60-73.
15. Sutar SV, Yeligar VC, Patil SS. Stability indicating forced degradation studies. Res J Pharm Technol. 2019;12 (1):429-33. doi:10.5958/0974-360X.2019.00078.7.
16. Patel NN, Kothari CS. Significance of force degradation study with respect to current pharmaceutical scenario: a critical review. Asian J Res Chem. 2013;6 (3):286-96.
17. Iram F, Iram H, Iqbal A, Hussain A. Forced degradation studies. J Anal Pharm Res. 2016;3:1-5. Available from: MedCrave Online PDF
18. Kumar HK, Reddy SP, Raju VK, Ravindranath LK. Forced degradation studies: practical approach-overview of regulatory guidance, and literature for the drug products and drug substances. Int Res J Pharm. 2013;4:78-85.
19. Bojana P, Markus D, Kappe CO. Microwave-assisted forced degradation using high-throughput microtiter platforms. J Pharm Biomed Anal. 2011;56:867-73.
20. Alsante KM, Martin L, Baertschi SW, et al. The role of degradation studies in drug development. Trends Anal Chem. 2013;49:71-88.
21. Husain A. Forced degradation studies. J Anal Pharm Res. 2016;3 (6).
22. International Council for Harmonisation. ICH Q1A (R2): Stability testing of new drug substances and products. Geneva: ICH; 2003.
23. Naveed S, Bashee S, Qamar F. Stability of a dosage form and forced degradation studies. J Bioequiv Availab. 2016;8:91-3.
24. International Council for Harmonisation. ICH Q1B: Photostability testing of new drug substances and products. Geneva: ICH; 1996.
25. International Council for Harmonisation. ICH Q2 (R1): Validation of analytical procedures: text and methodology. Geneva: ICH; 2005.
26. International Council for Harmonisation. ICH M4Q (R1): Common technical document for registration of pharmaceuticals. Geneva: ICH; 2002.
27. International Conference on Harmonisation. Impurities in new drug substances Q3A (R2). Geneva: ICH; 2006.
28. U.S. Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics: guidance for industry. Silver Spring (MD): FDA; 2015.
29. Razboršek MI, Ivanović M, Kolar M. Validated stability-indicating GC-MS method for characterization of forced degradation products. Molecules. 2021;26 (9):2475.
30. Rawat T, Pandey IP. Stability indicating methods for pharmaceutical analysis. J Pharm Anal.
31. Venkatesh DN, Shanmuga Kumar SD. Forced degradation: a review. Biomed J Sci Tech Res. 2022.
32. Deokate UA, Gorde AM. Forced degradation and stability testing: strategies and analytical perspectives. Pharma Tutor. 2014;2 (6):61-74.
33. Alvarenga Junior BR, Carneiro RLC. Chemometrics approaches in forced degradation studies of pharmaceutical drugs. Molecules. 2019;24 (20):3804.
34. Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, Parashar N, et al. Forced degradation studies to assess the stability of drugs and products. Trends Anal Chem. 2013;49:71-88.
35. Campbell JM, Colombo S, Doyle JL, Filoti DI, Hübner G, Magnenat L, et al. An industry perspective on the use of forced degradation studies to assess comparability of biopharmaceuticals. J Pharm Sci. 2024;113 (3):505-12.
36. Patil SV, Mali RB, Patil PP, Suryavanshi SS. ICH guidelines: stress degradation study. Int J Creat Res Thoughts. 2021;9 (7):e883-e888.
37. Bhaskar R, Ola M, Agnihotri V, Chavan A, Girase H. Current trend in performance of forced degradation studies for drug substance and drug products. J Drug Deliv Ther. 2018;8 (4):110-8. doi:10.22270/jddt.v8i4.1788.
38. Cornish L. Analytical techniques in stability testing. Separation Science.
39. Somase K, Rishipathak D. A review on forced degradation studies, stability indicating method and stability profile of few antiviral drugs. J Pharm Neg Results. 2022;13 (Special Issue 1):1315-31. doi:10.47750/pnr.2022.13.S01.158.
40. Bari SB, Jain SB, Shirkhedkar A, Sonawane A, Mhaske AJ, Gawad JB. Impurities in pharmaceuticals: a review. World J Pharm Res. 2015;4 (10):2932-47.
41. Balram V. Recent advances in the determination of elemental impurities in pharmaceuticals: status, challenges and moving frontiers. Trends Anal Chem. 2016;80:83-95. doi:10.1016/j.trac.2016.02.001.
42. Muller ALH, Oliveira JSS, Mello PA, Muller EI, Flores EMM. Study and determination of elemental impurities by ICP-MS in active pharmaceutical ingredients using single reaction chamber digestion in compliance with USP requirements. Talanta. 2015;136:161-9. doi:10.1016/j.talanta.2014.12.023.
43. Patel H, Patel B. Forced degradation studies: regulatory consideration and implementation. Int J Pharm Sci Rev Res. 2012;15 (1):78-85.
44. Jorvekar AR, More VS. Impurity profiling and degradation study: a review. Int J Res Anal Rev. 2022;9 (2).
45. Kachave RN, Bhandari DD, Pingale PL, Shinkar DM, Amrutkar SV. Impurity profiling and forced degradation studies of angiotensin (AT1) blockers: a review. Curr Pharm Anal. 2025. doi:10.1016/j.cpan.2025.01.005.
46. Patel AK, et al. Force degradation for pharmaceuticals: a review. Int J Sci Dev Res. 2023;8 (6):954-959.
47. Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Franca JR, et al. Pharmaceutical forced degradation (stress testing) endpoints: a scientific rationale and industry perspective. J Pharm Sci. 2023;112 (12):2948-64.